This brand name is authorized in Nigeria.
The drug VADILYN contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
6V9V2RYJ8N - PSEUDOEPHEDRINE HYDROCHLORIDE
|
|
Pseudoephedrine is a sympathomimetic agent with direct and indirect effects on adrenergic receptors. It has alpha and beta adrenergic activity and some stimulant effect on the central nervous system. The sympathomimetic effect of pseudoephedrine produces vasoconstriction which in turn relieves nasal congestion. |
|
2
|
UNII
TC2D6JAD40 - DIPHENHYDRAMINE HYDROCHLORIDE
|
|
Diphenhydramine is an ethanolamine-derivative antihistamine. It is an antihistamine with anticholinergic and marked sedative effects. It acts by inhibiting the effects on H1-receptors. Diphenhydramine is effective in reducing sleep onset (i.e., time to fall asleep) and increasing the depth and quality of sleep. |
|
3
|
UNII
1Q73Q2JULR - SODIUM CITRATE, UNSPECIFIED FORM
|
|
Sodium citrate has no relevant pharmacodynamic activity other than that caused by its alkalinity (e.g. its gastric acid neutralising capacity). Sodium citrate is a non-particulate antacid for use by mouth to prior to general anaesthesia for caesarean section. |
|
4
|
UNII
L7T10EIP3A - MENTHOL, UNSPECIFIED FORM
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| 04-4148 | Syrup | Vadilyn Syrup SYRUP 57 mg; 14 mg; 1.1 mg; 100 mg 1 x 100 mL (in amber PET bottle) | Oral Syrup | 30/04/2025 |
| B4-5271 | Syrup | Vadilyn Decongestant Syrup SYRUP 10 mg/5 mL; 14 mg/5 mL; 57 mg/5 mL; 1.1 mg/5 mL 100 mL (in amber PET bottle) | Oral Syrup | 30/11/2023 |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| R01BA52 | Pseudoephedrine, combinations | R Respiratory system → R01 Nasal preparations → R01B Nasal decongestants for systemic use → R01BA Sympathomimetics |
| R06AA52 | Diphenhydramine, combinations | R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AA Aminoalkyl ethers |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | 04-4148, B4-5271 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.